Study Summary
This study is evaluating whether muscle disuse may be a factor in muscle loss for individuals with cancer.
Eligible Conditions
- Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 3 Secondary · Reporting Duration: Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks
Week 8
Cross-sectional area of skeletal muscle fibers
Mitochondrial content
Mitochondrial function
Single muscle fiber contractile function
Whole muscle isokinetic function
Whole muscle isometric function
Whole muscle size
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Exercise
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Exercise · No Placebo Group · N/A
Exercise
Behavioral
Experimental Group · 1 Intervention: Exercise · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~760
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: difference between the change in the exercised and non-exercised leg from baseline to 8 weeks
Who is running the clinical trial?
University of VermontLead Sponsor
254 Previous Clinical Trials
3,742,797 Total Patients Enrolled
University of South CarolinaOTHER
177 Previous Clinical Trials
93,438 Total Patients Enrolled
Michael J. Toth, Ph.D.1.02 ReviewsPrincipal Investigator - University of Vermont
University of Vermont
2 Previous Clinical Trials
60 Total Patients Enrolled
Eligibility Criteria
Age 50 - 75 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments